Cargando…
COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months
INTRODUCTION: A large group of patients with chronic obstructive pulmonary disease (COPD) are exposed to an overload of oral corticosteroids (OCS) due to repeated exacerbations. This is associated with potential serious adverse effects. Therefore, we evaluated the impact of a recommended reduction o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530506/ https://www.ncbi.nlm.nih.gov/pubmed/31179005 http://dx.doi.org/10.1136/bmjresp-2019-000407 |
_version_ | 1783420670535794688 |
---|---|
author | Sivapalan, Pradeesh Ingebrigtsen, Truls Sylvan Rasmussen, Daniel Bech Sørensen, Rikke Rasmussen, Christian Madelaire Jensen, Camilla Bjørn Allin, Kristine Højgaard Eklöf, Josefin Seersholm, Niels Vestbo, Joergen Jensen, Jens-Ulrik Stæhr |
author_facet | Sivapalan, Pradeesh Ingebrigtsen, Truls Sylvan Rasmussen, Daniel Bech Sørensen, Rikke Rasmussen, Christian Madelaire Jensen, Camilla Bjørn Allin, Kristine Højgaard Eklöf, Josefin Seersholm, Niels Vestbo, Joergen Jensen, Jens-Ulrik Stæhr |
author_sort | Sivapalan, Pradeesh |
collection | PubMed |
description | INTRODUCTION: A large group of patients with chronic obstructive pulmonary disease (COPD) are exposed to an overload of oral corticosteroids (OCS) due to repeated exacerbations. This is associated with potential serious adverse effects. Therefore, we evaluated the impact of a recommended reduction of OCS duration in 2014 on the risk of pneumonia hospitalisation and all-cause mortality in patients with acute exacerbation of COPD (AECOPD). METHODS: This was a nationwide observational cohort study that was based on linked administrative registry data between 1 January 2010 and 31 October 2017. 10 152 outpatients with COPD (median age 70 years) treated with either a short (≤250 mg) or long course (>250 mg) of OCS for AECOPD were included in the study. Cox proportional hazards regression models were used to derive an estimation of multivariable adjusted HRs (aHRs) for pneumonia hospitalisation or all-cause mortality combined and pneumonia hospitalisation and all-cause mortality, separately. RESULTS: The long course of OCS treatment for AECOPD was associated with an increased 1-year risk of pneumonia hospitalisation or all-cause mortality (aHR 1.3, 95% CI 1.1 to 1.4; p<0.0001), pneumonia hospitalisation (aHR 1.2, 95% CI 1.0 to 1.3; p=0.0110) and all-cause mortality (aHR 1.8, 95% CI 1.5 to 2.2; p<0.0001) as compared with the short course of OCS treatment. These results were confirmed in several sensitivity analyses. CONCLUSION: The change of recommendations from long courses to short courses of OCS for AECOPD in 2014 was strongly associated with a decrease in pneumonia admissions and all-cause mortality, in favour of short courses of OCS. |
format | Online Article Text |
id | pubmed-6530506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-65305062019-06-07 COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months Sivapalan, Pradeesh Ingebrigtsen, Truls Sylvan Rasmussen, Daniel Bech Sørensen, Rikke Rasmussen, Christian Madelaire Jensen, Camilla Bjørn Allin, Kristine Højgaard Eklöf, Josefin Seersholm, Niels Vestbo, Joergen Jensen, Jens-Ulrik Stæhr BMJ Open Respir Res Chronic Obstructive Pulmonary Disease INTRODUCTION: A large group of patients with chronic obstructive pulmonary disease (COPD) are exposed to an overload of oral corticosteroids (OCS) due to repeated exacerbations. This is associated with potential serious adverse effects. Therefore, we evaluated the impact of a recommended reduction of OCS duration in 2014 on the risk of pneumonia hospitalisation and all-cause mortality in patients with acute exacerbation of COPD (AECOPD). METHODS: This was a nationwide observational cohort study that was based on linked administrative registry data between 1 January 2010 and 31 October 2017. 10 152 outpatients with COPD (median age 70 years) treated with either a short (≤250 mg) or long course (>250 mg) of OCS for AECOPD were included in the study. Cox proportional hazards regression models were used to derive an estimation of multivariable adjusted HRs (aHRs) for pneumonia hospitalisation or all-cause mortality combined and pneumonia hospitalisation and all-cause mortality, separately. RESULTS: The long course of OCS treatment for AECOPD was associated with an increased 1-year risk of pneumonia hospitalisation or all-cause mortality (aHR 1.3, 95% CI 1.1 to 1.4; p<0.0001), pneumonia hospitalisation (aHR 1.2, 95% CI 1.0 to 1.3; p=0.0110) and all-cause mortality (aHR 1.8, 95% CI 1.5 to 2.2; p<0.0001) as compared with the short course of OCS treatment. These results were confirmed in several sensitivity analyses. CONCLUSION: The change of recommendations from long courses to short courses of OCS for AECOPD in 2014 was strongly associated with a decrease in pneumonia admissions and all-cause mortality, in favour of short courses of OCS. BMJ Publishing Group 2019-03-30 /pmc/articles/PMC6530506/ /pubmed/31179005 http://dx.doi.org/10.1136/bmjresp-2019-000407 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Chronic Obstructive Pulmonary Disease Sivapalan, Pradeesh Ingebrigtsen, Truls Sylvan Rasmussen, Daniel Bech Sørensen, Rikke Rasmussen, Christian Madelaire Jensen, Camilla Bjørn Allin, Kristine Højgaard Eklöf, Josefin Seersholm, Niels Vestbo, Joergen Jensen, Jens-Ulrik Stæhr COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months |
title | COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months |
title_full | COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months |
title_fullStr | COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months |
title_full_unstemmed | COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months |
title_short | COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months |
title_sort | copd exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with copd followed for 12 months |
topic | Chronic Obstructive Pulmonary Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530506/ https://www.ncbi.nlm.nih.gov/pubmed/31179005 http://dx.doi.org/10.1136/bmjresp-2019-000407 |
work_keys_str_mv | AT sivapalanpradeesh copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT ingebrigtsentrulssylvan copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT rasmussendanielbech copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT sørensenrikke copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT rasmussenchristianmadelaire copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT jensencamillabjørn copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT allinkristinehøjgaard copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT eklofjosefin copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT seersholmniels copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT vestbojoergen copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months AT jensenjensulrikstæhr copdexacerbationstheimpactoflongversusshortcoursesoforalcorticosteroidsonmortalityandpneumonianationwidedataon67000patientswithcopdfollowedfor12months |